Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma
NL-OMON52620Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma and cutaneous malignancy comparing Nivolumab with Placebo (2 arms). Primary endpoint: Recurrence-free survival. Started Mar 2020; status: recruiting.
02
Drugs
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON52620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52620.